BioSpace News Archive

Equillium, Inc. announced that translational data supporting the potential of itolizumab in the treatment of graft-versus-host disease will be presented at the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood & Marrow Transplant Research being held February 19-23, 2020 at the World Center Marriott in Orlando, Florida.

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that it has commenced a proposed underwritten public offering of its common stock.

Bioasis Technologies Inc. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), today announced that it has applied for approval from the TSX Venture Exchange

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Kitakyushu General Hospital, a hospital in southwestern Japan, has entered into an agreement to lease and utilize a Senhance® System.

Bunzl Canada (bunzlcanada.ca) today announced its support to customers in helping prevent disease outbreaks such as Coronavirus continues to focus on best practice training and education in cleaning, sanitizing and disinfecting.

UMass Memorial Medical Center clinician who treats patients like family recognized for vital role in patient care

Varian announced it has signed an agreement with Massachusetts General Hospital to provide seven Varian radiotherapy systems and related services for advanced cancer treatment at its clinics.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2020 second quarter ended December 31, 2019 on Tuesday, February 11, 2020 after the close of the stock market.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share.

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share.